Semaglutide Dosing Guide
Evidence-based dosing protocols across 3 administration approaches.
Medical Disclaimer
Dosing Protocols
Weight Loss (Wegovy)
FDA ApprovedSubcutaneousDose Range
0.25–2.4 mg
Frequency
weekly
Source
Wegovy FDA Label; STEP trials (NEJM)
Escalation Schedule
Wk 1-4: 0.25 mg → Wk 5-8: 0.5 mg → Wk 9-12: 1.0 mg → Wk 13-16: 1.7 mg → Wk 17+: 2.4 mg
Dose titration designed to minimise GI side effects. BMI ≥30 or ≥27 with comorbidity.
Type 2 Diabetes (Ozempic)
FDA ApprovedSubcutaneousDose Range
0.5–2 mg
Frequency
weekly
Source
Ozempic FDA Label; SUSTAIN 1-7
Escalation Schedule
Start 0.25 mg × 4 wk → 0.5 mg → may increase to 1.0 mg → max 2.0 mg
Oral (Rybelsus)
FDA ApprovedOralDose Range
3–14 mg
Frequency
daily
Source
Rybelsus FDA Label
Escalation Schedule
3 mg × 30 d → 7 mg → may increase to 14 mg
Take on empty stomach ≥30 min before food/drink.
Administration
Delivery methods
Pending physician review — consult your provider before use.Updated 2026-04-10